CN101955511A - 氧化型谷胱甘肽及其碱金属盐的合成方法 - Google Patents
氧化型谷胱甘肽及其碱金属盐的合成方法 Download PDFInfo
- Publication number
- CN101955511A CN101955511A CN2009101814059A CN200910181405A CN101955511A CN 101955511 A CN101955511 A CN 101955511A CN 2009101814059 A CN2009101814059 A CN 2009101814059A CN 200910181405 A CN200910181405 A CN 200910181405A CN 101955511 A CN101955511 A CN 101955511A
- Authority
- CN
- China
- Prior art keywords
- sleep
- promoting factor
- alkali metal
- obtains
- synthetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 title claims abstract description 41
- -1 alkali metal salts Chemical class 0.000 title claims abstract description 25
- 229910052783 alkali metal Inorganic materials 0.000 title claims abstract description 12
- 108010053070 Glutathione Disulfide Proteins 0.000 title abstract description 7
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 title abstract 4
- 238000001308 synthesis method Methods 0.000 title abstract 3
- 238000006243 chemical reaction Methods 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 9
- LFHISGNCFUNFFM-UHFFFAOYSA-N chloropicrin Chemical compound [O-][N+](=O)C(Cl)(Cl)Cl LFHISGNCFUNFFM-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000012544 monitoring process Methods 0.000 claims abstract description 7
- 229910003002 lithium salt Inorganic materials 0.000 claims abstract description 5
- 159000000002 lithium salts Chemical class 0.000 claims abstract description 4
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract 3
- 108010066925 sleep-promoting factor B Proteins 0.000 claims description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- 238000003756 stirring Methods 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 10
- 229960004756 ethanol Drugs 0.000 claims description 10
- 235000019441 ethanol Nutrition 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000010189 synthetic method Methods 0.000 claims description 9
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000001953 recrystallisation Methods 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract description 8
- 229960003180 glutathione Drugs 0.000 abstract description 7
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- 108010024636 Glutathione Proteins 0.000 abstract 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 abstract 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 235000003969 glutathione Nutrition 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 241000321096 Adenoides Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101814059A CN101955511A (zh) | 2009-07-16 | 2009-07-16 | 氧化型谷胱甘肽及其碱金属盐的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101814059A CN101955511A (zh) | 2009-07-16 | 2009-07-16 | 氧化型谷胱甘肽及其碱金属盐的合成方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101955511A true CN101955511A (zh) | 2011-01-26 |
Family
ID=43483127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101814059A Pending CN101955511A (zh) | 2009-07-16 | 2009-07-16 | 氧化型谷胱甘肽及其碱金属盐的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101955511A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106526004A (zh) * | 2016-10-14 | 2017-03-22 | 安琪酵母股份有限公司 | 一种富含谷胱甘肽酵母抽提物中氧化型谷胱甘肽杂质的检测方法 |
WO2018225790A1 (ja) * | 2017-06-08 | 2018-12-13 | 協和発酵バイオ株式会社 | 酸化型グルタチオン・二カチオン塩の結晶及びその製造方法 |
CN114249794A (zh) * | 2021-12-22 | 2022-03-29 | 深圳瑞德林生物技术有限公司 | 一种氧化型谷胱甘肽的合成方法 |
-
2009
- 2009-07-16 CN CN2009101814059A patent/CN101955511A/zh active Pending
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106526004A (zh) * | 2016-10-14 | 2017-03-22 | 安琪酵母股份有限公司 | 一种富含谷胱甘肽酵母抽提物中氧化型谷胱甘肽杂质的检测方法 |
WO2018225790A1 (ja) * | 2017-06-08 | 2018-12-13 | 協和発酵バイオ株式会社 | 酸化型グルタチオン・二カチオン塩の結晶及びその製造方法 |
CN110678477A (zh) * | 2017-06-08 | 2020-01-10 | 协和发酵生化株式会社 | 氧化型谷胱甘肽二阳离子盐的晶体及其制造方法 |
JPWO2018225790A1 (ja) * | 2017-06-08 | 2020-04-09 | 協和発酵バイオ株式会社 | 酸化型グルタチオン・二カチオン塩の結晶及びその製造方法 |
US11407787B2 (en) * | 2017-06-08 | 2022-08-09 | Kyowa Hakko Bio Co., Ltd. | Crystal of oxidized glutathione dication salt and production method therefor |
JP7132917B2 (ja) | 2017-06-08 | 2022-09-07 | 協和発酵バイオ株式会社 | 酸化型グルタチオン・二カチオン塩の結晶及びその製造方法 |
CN114249794A (zh) * | 2021-12-22 | 2022-03-29 | 深圳瑞德林生物技术有限公司 | 一种氧化型谷胱甘肽的合成方法 |
CN114249794B (zh) * | 2021-12-22 | 2023-06-23 | 深圳瑞德林生物技术有限公司 | 一种氧化型谷胱甘肽的合成方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105586379B (zh) | 一种具有抑制癌细胞增殖作用的胶原蛋白活性肽的制备方法 | |
HRP20140194T1 (hr) | Nova sol metformin glicinat za kontrolu glukoze u krvi | |
CN104387320B (zh) | 一种高纯度米力农的制备方法 | |
CN101948524A (zh) | 富含多磷酸化多肽的酪蛋白水解物和制备方法 | |
CN101987094A (zh) | 门冬氨酸鸟氨酸注射液及其制备方法 | |
CN101955511A (zh) | 氧化型谷胱甘肽及其碱金属盐的合成方法 | |
CN104478877A (zh) | 制备雷迪帕韦中间体的方法 | |
CN109942452B (zh) | 一种络氨酸烯烃化衍生物及其制备与应用 | |
CN104418804B (zh) | 一种塞来昔布杂质及其制备方法、应用 | |
CN111960972B (zh) | 牛磺酸镁盐及牛磺酸镁配合物的制备工艺与应用 | |
CN108486185A (zh) | 一种制备肌肽的新工艺方法 | |
CN101838213A (zh) | 一种昆布氨酸及其可药用盐的制备方法 | |
CN101863819A (zh) | 一种制备l-焦谷氨酸镁的方法 | |
WO2015123998A1 (zh) | 一种维达列汀的合成方法 | |
CN102807601B (zh) | 氨基酰-色氨酰-5-甲氧色胺及其制备方法和应用 | |
CN104004040B (zh) | 一种利用草酰氯制备胞磷胆碱钠的方法 | |
CN107674902B (zh) | 一种具有降血糖功能的驼血多肽及其制备方法 | |
CN104177271B (zh) | 一种氯化乙酰左卡尼汀的制备方法 | |
CN101709038A (zh) | 一种从发酵液中提取l-苯丙氨酸的方法 | |
CN103451249A (zh) | 一种硫-稀丙基-l-半胱氨酸的制备方法 | |
CN101585813B (zh) | N-乙酰-l-肌肽的制备方法 | |
CN101575306B (zh) | 西维来司钠的制备方法 | |
CN111072755A (zh) | 力肽络合物、其药物组合物、其制备方法和应用 | |
CN105001197A (zh) | 一种阿格列汀衍生物ⅰ及其制备方法与应用 | |
CN111320673A (zh) | Fitc标记的帕西瑞肽衍生物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Zou Qiaogen Document name: Notification of Patent Invention Entering into Substantive Examination Stage |
|
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 210009 Room 1520, 15th Floor, Building A, Science and Technology Innovation Building, Nanjing Tech University, No. 5 Xin Model Road, Gulou District, Jiangsu Province Applicant after: Zou Qiaogen Address before: 8, building 26, 210009 Ma Jia street, Gulou District, Nanjing, Jiangsu Applicant before: Zou Qiaogen |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: NANJING HEALTHNICE MEDICAL TECHNOLOGY Co.,Ltd. Assignor: Zou Qiaogen Contract record no.: 2012320000065 Denomination of invention: Synthesis method of oxidized glutathione and alkali metal salts thereof License type: Exclusive License Open date: 20110126 Record date: 20120209 |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110126 |